Associated Papers
Patient-derived tumoroids recapitulate the morphologic and molecular features of pediatric brain tumors.
Soares-Ferreira B et al.
Npj Precision Oncology, 2025
Clinical and genomic features of Lynch syndrome differ by tumor site and disease spectrum.
Li S et al.
Nature Communications, 2025
A structure-based tool to interpret the significance of kinase mutations in clinical next generation sequencing in cancer.
Rangarajan A et al.
Frontiers in Oncology, 2025
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
He C et al.
Current Treatment Options in Oncology, 2024
Novel, clinically relevant genomic patterns identified by comprehensive genomic profiling in ATRX-deficient IDH-wildtype adult high-grade gliomas.
Bedics G et al.
Scientific Reports, 2023
The landscape of actionable genomic alterations in lung adenocarcinomas in India.
Sharma R et al.
Frontiers in Genetics, 2023
A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib.
Wong NACS et al.
Cancer Genetics, 2022
Ten-Year Survivorship in Patients with Metastatic Gastrointestinal Stromal Tumors.
Sutton TL et al.
Annals of Surgical Oncology, 2022
Convergent evolution and multi-wave clonal invasion in H3 K27-altered diffuse midline gliomas treated with a PDGFR inhibitor.
Arunachalam S et al.
Acta Neuropathologica Communications, 2022
Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.
Smrke A et al.
Future Oncology (london, England), 2020
Genetic rearrangements, hotspot mutations, and microRNA expression in the progression of metastatic adenoid cystic carcinoma of the salivary gland.
Andreasen S et al.
Oncotarget, 2018
Reproducible Analysis of Post-Translational Modifications in Proteomes--Application to Human Mutations.
Holehouse AS et al.
Plos One, 2015
High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
Künstlinger H et al.
Human Pathology, 2014
Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.
Dai J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Spectrum of mutations in gastrointestinal stromal tumor patients - a population-based study from Slovakia.
Minárik G et al.
Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica, 2013
Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors.
Belinsky MG et al.
Genes, Chromosomes & Cancer, 2013
Fresh surgical specimens yield breast stem/progenitor cells and reveal their oncogenic abnormalities.
Pommier SJ et al.
Annals of Surgical Oncology, 2012
Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.
Elling C et al.
Blood, 2011
High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors.
Belinsky MG et al.
Genes, Chromosomes & Cancer, 2009
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
Tang Z et al.
Oncogene, 2009
Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
Lasota J et al.
Histopathology, 2008
PDGFRalpha gene mutation and protein expression in gastrointestinal stromal tumors.
Chang HM et al.
Oncology, 2008
Prognostic implications of epidermal and platelet-derived growth factor receptor alterations in 2 cohorts of IDHwt glioblastoma.
Alnahhas I et al.
Neuro-oncology Advances, 0
Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG.
Tinkle CL et al.
Neuro-oncology Advances, 0